These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 16710021)
1. Epoetin alfa and darbepoetin alfa go head to head. Steensma DP; Loprinzi CL J Clin Oncol; 2006 May; 24(15):2233-6. PubMed ID: 16710021 [No Abstract] [Full Text] [Related]
2. Development of a strategy to successfully convert an ambulatory infusion center from epoetin alfa to darbepoetin alfa. Longfield V; Gebhart B; Hayward L J Support Oncol; 2005; 3(6 Suppl 4):8-9. PubMed ID: 16355548 [No Abstract] [Full Text] [Related]
3. Comment: Epoetin alfa versus darbepoetin alfa for cancer patients with treatment-related anemia. Yang MC Ann Pharmacother; 2006 May; 40(5):998-9; author reply 999. PubMed ID: 16670351 [No Abstract] [Full Text] [Related]
4. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia. Cersosimo RJ; Jacobson DR Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies. Case AS; Rocconi RP; Kilgore LC; Barnes MN Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064 [TBL] [Abstract][Full Text] [Related]
6. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa. Song X; Long SR; Marder WD; Sullivan SD; Kallich J Ann Pharmacother; 2009 Jul; 43(7):1203-10. PubMed ID: 19584392 [TBL] [Abstract][Full Text] [Related]
7. Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies. Scott SD Pharmacotherapy; 2002 Sep; 22(9 Pt 2):160S-165S. PubMed ID: 12222586 [TBL] [Abstract][Full Text] [Related]
8. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Schwartzberg LS; Yee LK; Senecal FM; Charu V; Tomita D; Wallace J; Rossi G Oncologist; 2004; 9(6):696-707. PubMed ID: 15561813 [TBL] [Abstract][Full Text] [Related]
9. Darbepoetin alfa and history of thromboembolic events. Ferretti G; Felici A; Cognetti F J Clin Oncol; 2009 Nov; 27(33):e211; author reply e212. PubMed ID: 19858373 [No Abstract] [Full Text] [Related]
10. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice. Patton J; Reeves T; Wallace J Oncologist; 2004; 9(4):451-8. PubMed ID: 15266098 [TBL] [Abstract][Full Text] [Related]
12. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Waltzman RJ Cancer; 2004 Apr; 100(7):1545-6; author reply 1546. PubMed ID: 15042691 [No Abstract] [Full Text] [Related]
13. Use and cost of erythropoiesis-stimulating agents in patients with cancer. Daniel G; Hurley D; Whyte JL; Willey V; Wilson M; Kallich J Curr Med Res Opin; 2009 Jul; 25(7):1775-84. PubMed ID: 19505205 [TBL] [Abstract][Full Text] [Related]
14. Darbepoetin alfa: potential role in managing anemia in cancer patients. Pirker R; Smith R Expert Rev Anticancer Ther; 2002 Aug; 2(4):377-84. PubMed ID: 12647980 [TBL] [Abstract][Full Text] [Related]
15. New oversight put in place for physicians giving anemia drugs to patients with cancer. Mitka M JAMA; 2010 Apr; 303(14):1355-6. PubMed ID: 20388885 [No Abstract] [Full Text] [Related]
17. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia. Charu V; Saidman B; Ben-Jacob A; Justice GR; Maniam AS; Tomita D; Rossi G; Rearden T; Glaspy J Oncologist; 2007 Oct; 12(10):1253-63. PubMed ID: 17962619 [TBL] [Abstract][Full Text] [Related]
18. Epoetin alfa and darbepoetin alfa for the treatment of chemotherapy-related anemia in cancer patients in Sweden: comparative analysis of drug utilization, costs, and hematologic response. Persson U; Borg S; Jansson S; Ekman T; Franksson L; Friesland S; Larsson AM Adv Ther; 2005; 22(3):208-24. PubMed ID: 16236682 [TBL] [Abstract][Full Text] [Related]
19. Clinical and economic comparison of epoetin alfa and darbepoetin alfa. Morreale A; Plowman B; DeLattre M; Boggie D; Schaefer M Curr Med Res Opin; 2004 Mar; 20(3):381-95. PubMed ID: 15025847 [TBL] [Abstract][Full Text] [Related]
20. Novel approaches to anemia associated with cancer and chemotherapy. Kolesar JM Am J Health Syst Pharm; 2002 Aug; 59(15 Suppl 4):S8-11. PubMed ID: 12166035 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]